Studies using a 3D tumoroid model of metastatic CRC demonstrate that cisplatin and 5-FU, commonly used chemotherapeutics, stimulate MMP9 promoter activity within residual cancer cells, despite differing effects on overall tumor growth. Here, MMP9 is linked to neoplasm.